Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2 by Zhou Yue et al.
ARTICLE
Received 6 Jan 2015 | Accepted 31 May 2015 | Published 9 Jul 2015
Crucial roles of RSK in cell motility by catalysing
serine phosphorylation of EphA2
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Crosstalk between inflammatory signalling pathways and receptor tyrosine kinases has been
revealed as an indicator of cancer malignant progression. In the present study, we focus on
EphA2 receptor tyrosine kinase, which is overexpressed in many human cancers. It has been
reported that ligand-independent phosphorylation of EphA2 at Ser-897 is induced by Akt.
We show that inflammatory cytokines promote RSK-, not Akt-, dependent phosphorylation of
EphA2 at Ser-897. In addition, the RSK–EphA2 signalling pathway controls cell migration
and invasion of metastatic breast cancer cells. Moreover, Ser-897-phosphorylated EphA2
co-localizes with phosphorylated active form of RSK in various human tumour specimens, and
this double positivity is related to poor survival in lung cancer patients, especially those with a
smoking history. Taken together, these results indicate that the phosphorylation of EphA2 at
Ser-897 is controlled by RSK and the RSK–EphA2 axis might contribute to cell motility and
promote tumour malignant progression.
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R
eceptor tyrosine kinases (RTKs) play central roles in
human tumorigenesis and malignant progression1,2.
EphA2, which belongs to the largest Eph subfamily
among RTKs, regulates tissue development and maintains
epithelial tissue homeostasis3,4. Overexpression of EphA2 is one
of the prognostic factors in progressive tumours, including lung,
breast, brain, ovarian, melanoma, prostate and urinary bladder
cancers. EphA2 expression correlates with cancer metastasis,
promotion of epithelial–mesenchymal transition (EMT) and
maintenance of cancer stem cell properties4–7. An EphA2
tyrosine kinase inhibitor has been shown to induce tumour
regression in human non-small cell lung cancer (NSCLC)
xenografts in vivo, indicating that EphA2 is a promising
molecular target in cancer therapy8. However, comprehensive
mechanisms for receptor function remain poorly understood.
RTKs are normally activated through their own tyrosine kinase
activity9. In addition to this classical activation model, it has
become evident that the phosphorylation of serine and threonine
residues plays key roles in ligand-controlled and ligand-
independent functions of RTKs10–16. We have reported that
tumour necrosis factor-a (TNF-a) induces the phosphorylation
of epidermal growth factor receptor (EGFR) at Thr-669 in
the juxtamembrane domain and Ser-1046/7 in the carboxy
(C)-terminal tail through extracellular signal-regulated kinase
(ERK) and p38 pathways, respectively11–13. Ser-1046/7 is
involved in clathrin-mediated endocytosis of EGFR and
Thr-669 phosphorylation causes negative feedback regulation of
its tyrosine kinase. Similarly, three serine residues in the C-tail of
fibroblast growth factor receptor 1 are phosphorylated by ERK,
protein kinase Ce (PKCe) and p90 ribosomal S6 kinase 2 (RSK2),
which are critical for negative feedback regulation and
endocytosis of the receptor14–16. Hence, study on serine/
threonine phosphorylation is essential to understand fully the
roles of RTKs in pathogenic alterations of cancers, but we are still
far from clarifying the whole picture.
Recently, increasing evidence has shown that upregulation of
EphA2 along with downregulation of its ligands, including
ephrin-A1, disrupts orderly epithelial adhesion of cancer cells,
suggesting ligand-independent functions of EphA2 in tumour
microenvironments4,17. Indeed, Miao et al.18 demonstrated an
alternative function of EphA2, in which ligand-independent Akt
phosphorylation of EphA2 at Ser-897 promotes growth factor-
induced cell polarization, lamellipodium protrusion and cell
migration, and is correlated with the tumour grade of human
astrocytoma. In contrast, ligand-dependent EphA2 tyrosine
kinase activation inhibited cell migration and invasion. A large
number of serine and threonine residues capable of being
phosphorylated have been identified by mass spectral analysis19;
therefore, further characterization of EphA2 phosphorylation is
essential for understanding the ligand-independent functions of
EphA2 in cancer cells.
In the present study, we try to determine whether an
inflammatory cytokine promotes EphA2 phosphorylation at
Ser-897. We show that TNF-a induces Ser-897 phosphorylation,
but, unexpectedly, it is directly regulated by the ERK–RSK
signalling pathway, but not by the PI3K–Akt pathway. Therefore,
we further characterize activation of the RSK–EphA2 pathway by
other factors activating ERK and their roles in regulating the cell
motility of human cancer cells. Furthermore, we investigate the
relationship between this pathway and clinical outcomes using
human lung cancer tissue specimens.
Results
Phosphorylation of EphA2 at Ser-897 is induced by TNF-a.
In our previous studies, we detected TNF-a-induced Ser/Thr
phosphorylation of EGFR12. To determine whether TNF-a also
induces the phosphorylation of EphA2, Zn2þ -Phos-tag
SDS–polyacrylamide gel electrophoresis (SDS–PAGE)20 that is
an approach for the detection and separation of phosphorylated
proteins, was used (Fig. 1a). First, we analysed the phosphoryla-
tion of EphA2 and EGFR in HeLa cells using Phos-tag
SDS–PAGE. Several shifted bands of EGFR were clearly
detected upon TNF-a stimulation, indicating different phos-
phorylation states. Similarly, but slightly delayed, two major
shifted bands of EphA2 were observed. These results indicate
that, in parallel with EGFR phosphorylation, EphA2 is targeted by
an inflammatory signalling pathway. We next used phospho-
Ser-897 EphA2 (pS-EphA2) antibody and phospho-Tyr-588
EphA2 (pY-EphA2) antibody in Phos-tag SDS–PAGE (Fig. 1b).
Upon stimulation with TNF-a, pS-EphA2 antibody recognized
two major bands that showed similar gel retardation in the total
EphA2 blot, whereas no band with a similar shift appeared in the
pY-EphA2 blot.
In normal SDS–PAGE, TNF-a and ephrin-A1 selectively
induced pS-EphA2 and pY-EphA2, respectively (Fig. 1c).
Selectivity of pS-EphA2 antibody to the phosphorylation of
Ser-897 was confirmed in HEK293 cells expressing Ser-897 to
Ala substitution mutant EphA2 (SA) (Supplementary Fig. 1a).
Moreover, pY-EphA2 was not induced until 60 min after TNF-a
stimulation, although pS-EphA2 was promoted from 10 min
and largely reduced at 60 min (Fig. 1d). This time course was
similar to that of the phosphorylation of EGFR at Thr-669 and
Ser-1046/7 (Fig. 1d). In addition, TNF-a and interleukin-1b
(IL-1b) induced pS-EphA2 in human lung adenocarcinoma
A549 cells (Supplementary Fig. 1b). We previously demonstrated
that TNF-a promotes EGFR endocytosis in a p38-dependent
manner11–12. Immunofluorescence analysis demonstrated that
EphA2 was not internalized and pS-EphA2 was localized on the
cell surface (Fig. 1e). Altogether, our results clearly demonstrated
that TNF-a induces the phosphorylation of EphA2 at Ser-897 in a
tyrosine kinase activity-independent manner.
Akt does not control Ser-897 phosphorylation of EphA2. Miao
et al.18 previously reported that Akt directly induces EphA2
phosphorylation at Ser-897 in glioma cells. Consequently, we
investigated whether Akt is also involved in pS-EphA2 in HeLa
cells. Cells were pre-incubated with PI3K inhibitor (LY294002) or
an allosteric Akt inhibitor (MK-2206) for 30 min and then
stimulated with TNF-a for 20 min (Fig. 2a). Unexpectedly,
pS-EphA2 was not inhibited by these inhibitors, while Akt
phosphorylation was significantly inhibited. We also confirmed
these results using immunofluorescence analysis (Supplementary
Fig. 2a). As used by Miao et al., we next attempted to evaluate
pS-EphA2 in T98G human glioblastoma cells stimulated with
TNF-a or FCS (Supplementary Fig. 2b). As shown in Fig. 2b,
MK-2206 and LY294002 abolished pS-EphA2 in neither TNF-a
stimulation nor FCS stimulation. Moreover, constitutively
present pS-EphA2 in MDA-MB-231 human breast cancer cells
harbouring KRAS and BRAF mutations and Panc-1 human
pancreatic cancer cells carrying KRAS mutation was also
resistant to PI3K inhibition (Fig. 2c). Collectively, these results
demonstrate that the phosphorylation of EphA2 at Ser-897 is not
catalysed by Akt.
TAK1 controls TNF-a-induced phosphorylation of EphA2. The
results for the PI3K–Akt pathway as shown above are reasonable
because we detected only slight activation of Akt in TNF-a-
treated HeLa cells (Fig. 2a). By contrast, transforming growth
factor-b-activated kinase 1 (TAK1) is a key kinase in the TNF-a
and IL-1b signalling pathway leading to MAPK and NF-kB
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activation21. RNAi knockdown experiments using shRNA or
siRNA against TAK1 demonstrated that TAK1 is essential
for TNF-a-induced pS-EphA2 (Fig. 2d,e). In addition, over-
expression of EphA2 with activated TAK1 in HeLa cells caused an
increase in EphA2 phosphorylation (Supplementary Fig. 2c).
These results indicate that EphA2 is phosphorylated by
downstream kinases of TAK1.
RSK inhibitor blocks phosphorylation of EphA2 at Ser-897. To
identify the kinases responsible for pS-EphA2, we obtained the
substrate sequence LOGO of Ser/Thr kinases from the Phospho
SitePlus database (http://www.phosphosite.org/homeAction.do)19.
Among Ser/Thr kinases, the LOGOs of RSK1 and RSK2,
downstream kinases of ERK, are similar to that of Akt. Akt and
RSKs are members of the AGC family kinases that share substrate
specificity characterized by Arg at position -3 relative to the
phosphorylated Ser/Thr19,22,23; therefore, we next qualified RSK as
a putative candidate for the kinase responsible for Ser-897
phosphorylation. As shown in Fig. 3a, TNF-a-induced pS-EphA2
was induced from 8 min, peaked at 14 min and was then gradually
downregulated, which closely correlated with the time course of
pRSK. Pretreatment with MEK inhibitor (U0126) or RSK inhibitor
(BI-D1870) abrogated the appearance of shifted bands in Phos-tag
SDS–PAGE and pS-EphA2 in normal SDS–PAGE as well as
pS-EphA2 staining in immunofluorescence, suggesting that the
ERK–RSK pathway controls pS-EphA2 (Fig. 3b,c, and
Supplementary Fig. 3a). We previously demonstrated that Thr-
669 phosphorylation of EGFR is also induced by the ERK
pathway12,13; however, it was inhibited by U0126 but not by
BI-D1870 (Fig. 3c), indicating that different kinases in the
ERK pathway control pS-EphA2 and pT-EGFR. Moreover, we
tried to examine the effects of various other stimuli that activate
RSK, including high osmotic stress (0.3 M NaCl), 12-o-
tetradecanoylphorbol 13-acetate (TPA) and EGF. As expected,
pS-EphA2 was strongly induced by all of these agents and it was
inhibited by BI-D1870, but not by LY294002 (Fig. 3d). U0126
and BI-D1870 also blocked EphA2 phosphorylation in
TNF-a-stimulated A549 cells (Supplementary Fig. 3b), in
FCS- or TNF-a-stimulated T98G and U-87 MG cells (Fig. 3e
and Supplementary Fig. 3c) and in MDA-MB-231 and Panc-1 cells
(Supplementary Fig. 3d). BI-D1870 enhanced phosphorylation of
RSK in some cell lines, including T98G and MDA-MB-231 cells
(Fig. 3e and Supplementary Fig. 3d), possibly due to inhibition
of the downstream negative feedback regulation24. However,
phosphorylation of Bad at Ser-112, an RSK substrate25, was
inhibited, indicating that BI-D1870 substantially inhibited RSK
kinase activity (Supplementary Fig. 3e). Collectively, these results
demonstrate that the phosphorylation of EphA2 at Ser-897 is
induced by RSK or its downstream kinases.
EphA2 at Ser-897 is directly phosphorylated by RSK. To
identify RSK as the kinase responsible for pS-EphA2, HEK293
cells were transfected with EphA2 and RSK1. Coexpression of
EphA2 with RSK1 induced Ser-897 phosphorylation of wild-type
EphA2 but not its SA mutant (Fig. 4a). Activation of
TAK1 caused RSK phosphorylation as well as pS-EphA2
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Figure 1 | Phosphorylation of EphA2 at Ser-897 is induced by TNF-a stimulation. (a) Whole-cell lysates from HeLa cells treated with TNF-a
(20 ng ml 1) for 10, 20 and 60 min were separated by Zn2þ -Phos-tag SDS–PAGE and immunoblotted with anti-EphA2 and EGFR antibodies.
(b) Whole-cell lysates from HeLa cells treated with TNF-a for 20 min were separated by Zn2þ -Phos-tag SDS–PAGE and immunoblotted with anti-EphA2,
pS-EphA2 and pY-EphA2. (c) Whole-cell lysates from HeLa cells treated with ephrin-A1 (100 ng ml 1) for 10 min or TNF-a for 20 min were separated by
normal SDS–PAGE and immunoblotted with anti-pS-EphA2, pY-EphA2, EphA2 and a-tubulin antibodies. (d) HeLa cells were stimulated with TNF-a for the
indicated periods. Whole-cell lysates were electrophoresed and probed with primary antibodies against pS-EphA2, pY-EphA2, EphA2, pT-EGFR, pS-EGFR,
EGFR and a-tubulin. (e) HeLa cells were stimulated with TNF-a for 20 and 60 min. After fixation and permeabilization, cells were immunofluorescently
stained with pS-EphA2, EphA2 or EGFR (clone LA1). Scale bar, 20mm. Shown are representative images from three independent experiments.
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(Supplementary Fig. 2c). In addition, constitutively active RSK1
but not kinase-dead RSK1 induced pS-EphA2, indicating that the
kinase activity of RSK1 is indispensable for pS-EphA2 (Fig. 4b).
Among the four members of the RSK family, RSK1 and RSK2
are major isoforms involved in cancer metastasis and EMT26,27;
therefore, we carried out an RNAi experiment on RSK1 and
RSK2. As shown in Fig. 4c, single knockdown of neither RSK1
nor RSK2 reduced pS-EphA2, but RSK1/2 double knockdown
attenuated pS-EphA2 completely. Moreover, pS-EphA2 was
partially recovered by RSK1 re-expression (Supplementary
Fig. 4), suggesting that pS-EphA2 is regulated redundantly by
RSK1 and RSK2. Consequently, to obtain direct evidence for the
catalysis of EphA2 phosphorylation, we performed an in vitro
kinase assay using recombinant kinases and found that both
GST-RSK1 and GST-RSK2 phosphorylated Ser-897 of GST-
EphA2 (Fig. 4d). Collectively, these results demonstrate that the
phosphorylation of Ser-897 is catalysed by RSK1/2 directly.
RSK–EphA2 axis is involved in cell motility. It has been
reported that Ser-897 phosphorylation of EphA2 promotes cell
migration and invasion18. RSK1 and RSK2 are also known as key
kinases for metastatic properties in various types of cancer
cell26,27; therefore, we tried to determine whether the novel
RSK–EphA2 axis induces cell motility. MDA-MB-231 cells, in
which the RSK–EphA2 axis is constitutively activated (Fig. 5a),
were adopted for a scratch assay. Treatment of RSK inhibitor
BI-D1870 continuously inhibited pS-EphA2 for 48 h (Fig. 5b). We
confirmed that there were no significant differences in cell
proliferation and cell death between BI-D1870-treated cells and
control cells (Supplementary Fig. 5a and b). Although cells
migrated to the scratched area in the control sample, significant
attenuation of cell migration was observed in BI-D1870-treated
cells (Fig. 5c). Similar results were obtained using siRNAs
against RSK1 and RSK2 (Supplementary Fig. 5c and d).
Immunofluorescence staining on the migration border
demonstrated that pS-EphA2 and EphA2 were preferentially
localized in the migrating front with F-actin in lamellipodia in
control cells (Fig. 5d,e). On the other hand, BI-D1870 not only
inhibited staining of pS-EphA2 but also collapsed the elongated
and polarized morphology. In addition, the formation of
lamellipodia was notably interfered with and EphA2 diffused all
over the cells by the inhibition of RSK activity (Fig. 5e,f).
Moreover, BI-D1870 and RSK1/2 knockdown reduced invasive
ability in Matrigel-coated chamber (Supplementary Fig. 5e and f).
These results suggested that RSK1/2 control cell motility by
maintaining pS-EphA2 localization at the edge in the direction of
movement, such as in lamellipodia.
To provide direct evidence for the role of the RSK–EphA2 axis
in cell motility, the expression of EphA2 in EphA2-knockdown
cells was restored by the transfection of siRNA-resistant
complementary DNA encoding EphA2 (Fig. 5g,h). Cell migration
reduced by EphA2 knockdown was recovered by re-expression of
kinase-dead EphA2, but not that of its S897A mutant. In addition,
TNF-a-induced migration of A549 cells was inhibited by
BI-D1870 or EphA2 knockdown (Supplementary Fig. 6a and b).
Collectively, these results indicate that RSK-mediated Ser-897
phosphorylation of EphA2 is indispensable for cell motility in a
tyrosine kinase activity-independent fashion.
Molecular-targeted agents inhibited EphA2 phosphorylation.
A large proportion of driver oncogene products are known to
activate the ERK signalling pathway constitutively to induce cell
proliferation and metastatic properties28,29. First, we studied
human melanoma cell lines with BRAF-V600E mutation (A2058,
SK-MEL-28, A375, UACC62 and UACC257) and NRAS-Q61R
mutation (SK-MEL-2). Among these melanoma cell lines, A2058,
A375, UACC257 and SK-MEL-2 expressed total EphA2
protein and pS-EphA2 constitutively (Fig. 6a). Vemurafenib, a
BRAF inhibitor, reduced pS-EphA2 in cells harbouring BRAF
mutation, but rather increased pS-EphA2 in NRAS-mutated SK-
MEL-2 cells (Fig. 6a) as well as in KRAS-mutated DLD-1 human
colorectal cancer cells (Fig. 6b). Paradoxical upregulation of pS-
EphA2 in RAS-mutated cells might be controlled by the
activation of CRAF30,31. Trametinib, an MEK inhibitor used for
the treatment of melanoma in the clinical setting32, also inhibited
pS-EphA2 (Supplementary Fig. 7). Most importantly, RSK
inhibitor
BI-D1870 abrogated pS-EphA2 in all these cell lines (Fig. 6a,b).
We next analysed pS-EphA2 in human NSCLCs with EGFR
exon 19 deletion (PC-9, HCC827, HCC4006 and NCI-H1650),
EML4-ALK fusion (H2228) and KRAS mutation (A549).
BI-D1870, U0126 and each targeted tyrosine kinase inhibitor,
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Figure 2 | The phosphorylation of EphA2 at Ser-897 is induced by TAK1, but not by Akt. (a,b) HeLa (a) or T98G (b left) cells were pre-treated
with LY294002 (10mM) or MK-2206 (10mM) for 30 min and then stimulated with TNF-a for 20 min. T98G cells were starved using FCS-free medium
for 24 h, treated with LY294002 for 30 min and then treated with 10% FCS for 10 min (b, right). (c) MDA-MB-231 and Panc-1 cells were treated with
LY294002 for 30 min. (d) HeLa cells stably transfected shRNA expression vectors against luciferase and TAK1 were stimulated with TNF-a for 20 min.
(e) HeLa cells were transfected with siRNAs against TAK1 or negative control. At 72 h post transfection, cells were treated with TNF-a for 20 min.
Whole-cell lysates were immunoblotted with anti-pS-EphA2, EphA2, pAKT, pRSK, RSK1, RSK2, TAK1, b-actin and a-tubulin antibodies.
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including gefitinib and crizotinib, abrogated pS-EphA2, indicat-
ing that the RSK–EphA2 axis was constitutively activated by
driver oncogene products in all these lung cancer cells (Fig. 6c).
Overall, these results highlight that the RSK–EphA2 axis is under
the control of driver oncogenes, and suggest that molecular-
targeted agents have the potential to block cancer migration and
invasion via inhibition of the RSK–EphA2 pathway.
Immunohistochemical co-localization of pS-EphA2 and pRSK.
We immunohistochemically investigated pRSK and pS-EphA2
using a multi-cancer tissue microarray, which included 1,010
cores from 13 organ cancer tissues. We found double-positive
samples in various cancers except for one stomach sample exhi-
biting pS-EphA2 positivity and pRSK negativity, suggesting a
strong signalling correlation between EphA2 and RSK in human
cancer tissues (Supplementary Fig. 8a–f). Figure 7a showing
typical specimens of lung adenocarcinoma and squamous cell
carcinoma indicates that pS-EphA2 and pRSK were potentially
co-localized. Almost completely matched expression of pS-EphA2
and pRSK was also observed in lung adenocarcinoma tissues with
activating EGFR mutations, including exon 19 deletion (Fig. 7b
and Supplementary Fig. 8g). High-power magnifying images
demonstrated that pS-EphA2 was stained mainly in the cell
membrane, but also in the cytoplasm (Fig. 7a and Supplementary
Fig. 8g). On the other hand, pRSK was located in both cytoplasm
and nucleus (Fig. 7a and Supplementary Fig. 8g). Moreover,
selective luminal membrane-side staining was an interesting
observation in colon cancer tissues (Supplementary Fig. 8a).
Collectively, these results suggest functional correlation between
the serine phosphorylation of EphA2 and the activation of RSK in
human tumour microenvironments.
Poor prognosis of pS-EphA2/pRSK double-positive patients.
It has been demonstrated that EphA2 protein expression is
increased in smokers and predicts poor survival in NSCLCs33.
Therefore, we finally explored the role of the RSK–EphA2
pathway in patients’ prognosis using a lung cancer tissue
microarray, which consists of a total of 353 samples, including
175 adenocarcinomas, 88 squamous cell carcinomas and others.
There were no significant differences between clinicopathological
factors, including smoking, and the expression of pS-EphA2/
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Figure 3 | Phosphorylation of pS-EphA2 is induced by RSK. (a) HeLa cells were stimulated with TNF-a for the indicated periods. Whole-cell lysates were
immunoblotted with anti-pS-EphA2, EphA2, pRSK, RSK1, RSK2 and a-tubulin antibodies. (b,c) Whole-cell lysates from HeLa cells pre-treated with
LY294002 (10mM), SB203580 (10 mM), U0126 (5 mM) or BI-D1870 (10 mM) for 30 min and then stimulated with TNF-a for 20 min were separated
by Zn2þ -Phos-tag SDS–PAGE and immunoblotted with anti-EphA2 and pS-EphA2 antibodies (b), or by normal SDS–PAGE and immunoblotted with
anti-pS-EphA2, EphA2, pT-EGFR, pS-EGFR, EGFR, pRSK, RSK1, RSK2 and a-tubulin antibodies (c). (d) HeLa cells were pre-treated with LY294002 or
BI-D1870 for 30 min and then stimulated with NaCl (0.3 M), TPA (100 ng ml 1) or EGF (10 ng ml 1) for 10 min. Whole-cell lysates were immunoblotted
with primary antibodies against pS-EphA2, EphA2, pRSK, RSK1, RSK2, pAKT and a-tubulin. (e) T98G and U-87 MG cells starved in FCS-free medium for
24 h were treated with LY294002, MK-2206, U0126 and BI-D1870 for 30 min and then stimulated with 10% FCS for 10 min. Whole-cell lysates were
immunoblotted with primary antibodies against pS-EphA2, EphA2, pRSK, RSK1, RSK2, pAKT, pERK and a-tubulin.
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difference between pRSK expression (Fig. 7c,e) or total RSK1
expression (Supplementary Fig. 9a and b) and overall survival
both in all patients and in patients with a smoking history,
pS-EphA2/pRSK double-positive patients had poorer survival
duration than the pS-EphA2-negative/pRSK-positive group
(Fig. 7d). Moreover, a drastic difference was observed
in smoking patients (Fig. 7f). These results indicate that
RSK-mediated serine phosphorylation of EphA2 is involved in
poorer overall survival in lung cancer.
Discussion
The phosphorylation of EphA2 at Ser-897 has been characterized
as an important reaction regulating tumour progression of
human glioma18. Akt has been identified to be responsible for
ligand-independent migration and invasion by inducing Ser-897
phosphorylation, in which phospho-(Ser/Thr) Akt substrate
antibody that recognizes [RXXpS/pT] has mainly been used to
detect the phosphorylated protein. EphA2 amino acids 894–897
[RLPpS] completely match the consensus sequence; however, it is
also a putative substrate of RSK, as shown in the PhosphoSitePlus
database19. Indeed, we report here that RSK1 and RSK2, but not
Akt, catalyse Ser-897 phosphorylation directly in cytokine,
growth factor and oncogenic signalling pathways in all of the
human cancer cells that we tested, including glioma cells. In
addition, the immunohistochemical co-localization of pS-EphA2
and activated RSK supports the existence of a novel RSK–EphA2
signalling pathway in tumour microenvironments. Nonetheless, it
is still essential to consider carefully the contribution of Akt in
EphA2 phosphorylation because Akt is reported to activate ERK
in some conditions such as stimulation with platelet-derived
growth factor.
Two major pSer-897 bands were detected in immunoblot
results using Phos-tag SDS–PAGE (Fig. 1a,b, Figs 3b and 5a).
These results demonstrate that there is at least one additional
phosphorylation site other than Ser-897 in EphA2. In the
PhosphoSitePlus database, more than 10 serine and threonine
residues are deposited as putative phosphorylation sites in the
intracellular domain of human EphA2 (ref. 19). In particular, the
amino-acid sequence around Ser-897 (SIRLPS897TSGS) contains
several serine and threonine residues. Therefore, we are now
trying to identify new phosphorylation sites and their responsible
kinases to understand fully the tyrosine kinase- and ligand-
independent prometastatic function of EphA2. In addition, the
amino acid corresponding to Ser-897 and surrounding amino
acids are largely conserved in EphA1, another RTK of the Eph
receptor family, which is also involved in invasion, metastasis and
poor prognosis of cancer patients34,35. Therefore, although the
level of EphA1 expression in human cancer cells used in this
study is very low (Supplementary Fig. 10), it is essential to
characterize whether the serine residue of EphA1 is a substrate for
RSK or Akt.
RSK has been reported to induce cell proliferation through
promoting cell cycle progression and cell survival through
modulating activity of the BCL2 family in various malignancies26.






















































































Figure 4 | EphA2 at Ser-897 is phosphorylated by RSK1/2. (a,b) HEK293 cells were transfected with expression vectors for EphA2, RSK1 and its
substitution mutants. At 24 h post transfection, whole-cell lysates were immunoblotted with anti-pS-EphA2, pY-EphA2, EphA2, pRSK, RSK1 and a-tubulin
antibodies. (c) HeLa cells were transfected with siRNAs against RSK1, RSK2 or negative control. At 72 h post transfection, cells were stimulated with TNF-a
for 20 min. Whole-cell lysates were immunoblotted with primary antibodies against pS-EphA2, EphA2, pRSK, RSK1, RSK2 and a-tubulin. (d) Recombinant
human GST-EphA2 was incubated with recombinant human active GST-RSK1 or RSK2 in the absence or presence of BI-D1870 (0.1mM) at 30 C for 30 min.
The reaction mixtures were analysed by immunoblotting with anti-pS-EphA2, EphA2, RSK1 and RSK2 antibodies.
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of effects that promote cancer migration, invasion, metastasis and
EMT both in vitro and in vivo27. For example, Doehn et al.36
reported that treatment with several RSK inhibitors, including
BI-D1870, reduced migration as well as blocked TGF-b/TNF-a-
induced, ERK-dependent EMT through inhibition of the FRA1-
and c-Jun-dependent transcriptional programme of prometastatic
genes, including those encoding extracellular cell matrix (ECM)
components and matrix metalloproteinases (MMPs). In the
present study, RSK1/2 were shown to have redundant roles in
promoting both EphA2 phosphorylation and cell migration,
supporting the metastasis-promoting ability of RSK1/2.
In addition, RSK can regulate cell migration by suppressing
integrin-mediated cell adhesion through phosphorylation of
the scaffolding protein filamin A at Ser-2125 (refs 37,38).
Interestingly, EphA2 on the cell surface can also interact with
integrins to regulate cell adhesion. Moreover, both RSK and
EphA2 have been demonstrated to control RhoA and RhoG small
GTPase activities27,39–41. In particular, Kawai et al.42 reported
that pS-EphA2 promotes the interaction of EphA2 with ephexin4
to induce the activation of RhoG. Consequently, our new
finding on the functional connection between RSK and EphA2
encourages further study to characterize fully the cooperation of
these two kinases with integrins and Rho GTPases in the motility
of cancer cells, cell–cell adhesion and cell–ECM interaction.
Determination of the mechanism maintaining tumour
stemness is one of the most important challenges in current
oncology and might also involve collaboration of RSK and
EphA2. Binda et al.7 showed that EphA2 drives self-renewal and
tumorigenicity in cancer stem cells derived from human
glioblastoma, in which a strong signal for pS-EphA2 was
detected in stem-like tumour propagating cells, but not in
differentiated astrocytoma and neuroblastoma, in an ephrin-A
ligand-independent manner. In addition, infiltrative invasion of
glioma stem cells expressing EphA2 in vivo, which is completely
independent of ephrin-A1, A3 and A4 ligands, was disrupted by
S897A mutation43. Stratford et al.44 reported that targeting RSK2
with siRNA or small molecule inhibitors eliminates tumour-
initiating cells in triple-negative breast cancers. Combining these
reports with our results establishes the new idea that the
RSK–EphA2 axis might have an important function in the
maintenance of cancer stem properties; therefore, detailed study
is needed to understand fully their roles in tumour progression.
EphA2 expression has been considered to be associated













































































































Figure 5 | The RSK–EphA2 axis controls cell motility. (a) Whole-cell lysates from HeLa cells treated with TNF-a for 20 min or untreated MDA-MB-231
cells were separated by Zn2þ -Phos-tag SDS–PAGE and immunoblotted with anti-EphA2 antibody. (b–f) MDA-MB-231 cells were pre-treated with
BI-D1870 (10mM) for 30 min and then scratched with a pipette tip. After 48 h of incubation, whole-cell lysates were immunoblotted with primary
antibodies against pS-EphA2, EphA2 and b-actin (b) Migrated cells were counted manually under a microscope (c) Data are the means±s.d. of at
least three fields. Similar results were obtained in at least three independent experiments. *Po0.05 by Student’s t-test. At the same time, the migration
border cells were immunofluorescently stained with anti-pS-EphA2 or EphA2 antibodies (d,e) and cells harbouring lamellipodia were counted manually
under a microscope (f) Scale bar, 20mm. Data are the means±s.d. of at least three fields. Similar results were obtained in at least three independent
experiments. *Po0.05 by Student’s t-test. (g,h) MDA-MB-231 cells were transfected with siRNA against EphA2 or negative control and EphA2
mutation-expression plasmids. The immunoblotting results from whole-cell lysates with anti-pS-EphA2, EphA2 and b-actin antibodies are shown in g
and the results of scratch assay are shown in h. Data are the means±s.d. of at least three fields. Similar results were obtained in at least three independent
experiments. *Po0.05 by analysis of variance followed by Tukey–Kramer HSD test.
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Brannan et al., for example, reported that EphA2 expression was
positively correlated with activated EGFR, KRAS mutation,
smoking history, poor prognosis, early recurrence and
metastasis33,45. Here, we demonstrated that RSK-mediated
EphA2 phosphorylation at Ser-897 is involved in poor patient
survival, especially in smokers. It is well known that smoking is
frequently associated with KRAS mutation47. In addition, KRAS
activation of the ERK pathway induces EphA2 expression in
cultured cancer cells in vitro33. Considering these observations
together with our results, KRAS-mediated activation of the
ERK–RSK pathway regulates not only EphA2 protein expression
but also the phosphorylation of EphA2, which consequently
results in high level expression of pS-EphA2 leading to cancer
metastasis. In addition to KRAS mutation, we demonstrated that
EGFR mutation and ALK fusion, major causes of NSCLCs, are
other potential mechanisms to activate RSK in human NSCLCs
(Fig. 6). In contrast, the regulation of EphA2 overexpression is
still largely unknown; therefore, further detailed study is needed
to understand fully the molecular mechanisms behind the high
expression of pS-EphA2 in cancer cells.
The role of pS-EphA2 has also been demonstrated in
glioblastoma multiforme, in which a high level of pS-EphA2
was only detected in grade IV human astrocytomas18. These
results suggest that the RSK–EphA2 axis is a common
pathophysiological signature for human cancers. In the present
study, we demonstrated that BRAF-V600E evoked RSK-mediated
EphA2 phosphorylation in melanoma cells. It has been
demonstrated that both RSK and EphA2 play critical oncogenic
and cancer progressive roles in melanoma48,49. Moreover, it has
become evident that ligand-independent EphA2 signalling
is a mediator of vemrafenib resistance50,51. Recent clinical
trials clarified that combined MEK (trametinib) and BRAF
(dabrafenib) inhibition is effective molecular-targeted therapy for
melanoma patients harbouring BRAF mutation, suggesting that
the RSK–EphA2 pathway inhibition affects the therapeutic
efficacy52. As shown in Supplementary Fig. 7, treatment
of trametinib resulted in effective downregulation of the
RSK–EphA2 pathway; therefore, it is one possible strategy for
intervention of phosphorylation of EphA2 for the treatment of
cancers in a clinical context.
In summary, we have demonstrated the previously unknown
connection of RSK to EphA2, and this pathway is involved in the
malignant progression of cancer cells, such as migration and
invasion. In addition to EphA2, many other RTKs are over-
expressed in tumour tissues and involved in oncogenesis and
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Figure 6 | Molecular-targeted agents inhibited pS-EphA2. (a) Human melanoma cells (A2058, SK-MEL-28, A375, UACC62, UACC257 and SK-MEL-2),
(b) DLD-1 colon cancer cells and (c) lung adenocarcinoma cells (PC-9, HCC827, HCC4006, NCI-H1650, H2228 and A549) were treated with vemurafenib
(1mM), BI-D1870 (10mM), gefitinib (1 mM), crizotinib (10mM) or U0126 (5mM) for 30–60 min. Whole-cell lysates were immunoblotted with primary
antibodies against pS-EphA2, EphA2, pRSK, RSK1, RSK2, pY-EGFR, EGFR, b-actin and a-tubulin.
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on ligand-controlled and ligand-independent serine and
threonine phosphorylation is the next challenge to elucidate new
unknown functions of RTKs, to illustrate cancer pathology and to
identify new molecular targets for pharmacological interventions.
Methods
Antibodies and reagents. The phospho-specific antibodies against EphA2
(Ser-897; #6347 and Tyr-588; #12677), Akt (Ser-473; #9271), RSK1 (Ser-380;
cross-reacting with RSK2 Ser-386; #11989), ERK (Thr-202/Tyr-204; #9101) and
EGFR (Thr-669; #3056, Ser-1046/7; #2238 and Tyr-1068; #2236) were purchased
from Cell Signaling Technology (Danvers, MA, USA). Antibodies against total
EphA2 (C-20; sc-924), RSK1 (C-21; sc-231), RSK2 (C-19; sc-1430), EGFR
(1005; sc-03), TAK1 (M-579; sc-7162), b-actin (I-19; sc-1616) and a-tubulin
(B-7; sc-5286) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Recombinant human TNF-a, ephrin-A1-Fc chimera and EGF were obtained
from R&D Systems (Minneapolis, MN, USA); recombinant human active
GST-EphA2, GST-RSK1 and GST-RSK2 protein were from Carna Biosciences
(Kobe, Japan); anti-EGFR monoclonal antibody (clone LA1; 05-101) was from
Millipore (Billerica, MA, USA); Phos-tag ligand and TPA were from Wako Pure
Chemical Industries (Osaka, Japan); LY294002, SB203580 and U0126 were
from Merck Biosciences (Darmstadt, Germany); MK-2206 was from Active
Biochemicals (Wan Chai, Hong Kong); BI-D1870 and crizotinib were from
BioVision (Milpitas, CA, USA); gefitinib was from Cayman Chemical (Ann Arbor,
MI, USA); and vemurafenib was from LC Laboratories (Woburn, MA, USA). All of
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Figure 7 | pS-EphA2 and pRSK are co-localized in cancer patients’ specimens and the RSK–EphA2 axis is associated with the overall survival of lung
cancer patients. (a) A multi-cancer tissue microarray, including 1,010 cores from 13 organ cancer tissues, was adopted for immunohistochemical staining
using primary antibodies against pS-EphA2 and pRSK. Typical staining images of lung cancer tissues, including adenocarcinoma (AD) and squamous cell
carcinoma (SCC), at low- and high-power magnifications are shown. Scale bar, 20mm. (b) Typical immunohistochemical staining of pS-EphA2 and pRSK in
EGFR-mutated (exon 19 deletion) lung adenocarcinoma tissues are shown. Scale bar, 20mm. (c–f) Postoperative overall Kaplan–Meier survival curves of all
the lung cancer patients (c,d) or smoking patients (e,f) were compared according to pRSK negativity or positivity (c,e) or pS-EphA2/pRSK double positivity
(d,f) P values were calculated by the log-rank tests.
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Cell cultures. HeLa, HEK293, MDA-MB-231, Panc-1 and A375 cells were
obtained from the American Type Culture Collection (ATCC, Rockville, TX, USA)
and maintained in Dulbecco’s modified Eagle’s medium (high-glucose condition;
Life Technologies Corporation, Carlsbad, CA, USA) supplemented with 10%
fetal calf serum, 100 U ml 1 penicillin and 100mg ml 1 streptomycin (Meiji
Seika Pharma, Tokyo, Japan) at 37 C in 5% CO2. DLD-1 (kindly gifted by
Dr K. Tsukada, University of Toyama, Toyama, Japan), A2058 (ATCC),
SK-MEL-28, SK-MEL-2, UACC62, UACC257 (kindly gifted by Dr D. E. Fisher,
Massachusetts General Hospital, Boston, MA, USA), PC-9 (kindly gifted by
Dr K. Kiura, Okayama University, Okayama, Japan), HCC827 (ATCC), HCC4006
(kindly gifted by Dr A.F. Gazdar, University of Texas Southwestern Medical
Center, Dallas, TX, USA), NCI-H1650 (ATCC), H2228 (ATCC) and A549 (ATCC)
cells were cultured in RPMI 1640 medium (Life Technologies Corporation)
supplemented with 10% fetal calf serum, 100 U ml 1 penicillin and 100mg ml 1
streptomycin at 37 C in 5% CO2. T98G and U-87 MG cells kindly gifted by
Dr M. Takeya (Kumamoto University, Kumamoto, Japan) and T. Imanaka
(University of Toyama), respectively were maintained in Eagle’s MEM (Nissui,
Tokyo, Japan) supplemented with 10% fetal calf serum and 2 mM L-glutamine
(Life Technologies Corporation) at 37 C in 5% CO2. Stably Luc- and
TAK1-knocked down HeLa cells were as described previously12.
Transfection of plasmid DNAs. Expression vectors for human wild-type (WT)
and kinase-dead (KD) mutant EphA2 were provided by Dr Haruhiko Sugimura
(Hamamatsu University School of Medicine, Hamamatsu, Japan) and were as
described previously53,54. The expression vector for human RSK1 was provided by
Dr Yoshikazu Sugimoto (Keio University, Tokyo, Japan) and was as described
previously55. HEK293 and MDA-MB-231 cells were transfected using
Lipofectamine 2000 or Lipofectamine LTX (Life Technologies Corporation) in
accordance with the manufacturer’s instructions. S897A(SA)-EphA2 or KDSA-
EphA2 substitution mutations for WT-EphA2 or KD-EphA2 expression plasmids,
respectively, and constitutively active (CA-RSK1 (Y702A)) and kinase-dead
(KD-RSK1 (K94R/K447R)) mutations for RSK1 expression plasmid were generated
by PCR with PrimeSTAR DNA polymerase (Takara Bio, Shiga, Japan).
RNA interference. Small interfering RNAs (siRNAs) were synthesized at Life
Technologies Corporation (Stealth RNA interference) or Hokkaido System Science
Co., Ltd. (Sapporo, Japan). The target sequences were as follows: 50-CCAUGCUG
GCAGGAUAUACUCCAUU-30 (RSK1), 50-GGGAGGAGAUUUGUUUACACG
CUUA-30 (RSK2), 50-UGGAGUCCAUCAAGAUGCAGCAGUA-30 (EphA2),
50-UGGCUUAUCUUACACUGGA-30 (TAK1) and 50-UAAUGUACUGCGCGU
GGAGAGGAA-30 (negative control). HeLa and MDA-MB-231 cells were trans-
fected with siRNAs at a final concentration of 20 to 100 nM using Lipofectamine
Reagent or Lipofectamine LTX (Life Technologies Corporation) in accordance with
the manufacturer’s instructions, respectively.
Immunoblotting. Whole-cell lysates were prepared with lysis buffer (25 mM
HEPES (pH 7.7), 0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton
X-100, 20 mM b-glycerophosphate, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 10 mg ml 1 aprotinin and
10mg ml 1 leupeptin). The lysates were mixed with the same volume of
SDS–PAGE sample buffer (100 mM Tris-HCl (pH 6.8), 2.0% SDS, 70 mM DTT,
10% glycerol and 0.10% bromophenol blue) and heated at 95 C for 5 min. Samples
were resolved using 6.5, 7.5 or 10% SDS–PAGE gel and transferred to an
Immobilon-P nylon membrane (Millipore, Billerica, MA, USA). The membrane
was treated with BlockAce (Dainippon Sumitomo Pharmaceutical Co., Ltd.,
Osaka, Japan) and probed with primary antibodies (diluted 1:1,000, except for
phospho-ERK, RSK1, b-actin and a-tubulin, which were diluted 1:4,000). The
antibodies were detected using horseradish peroxidase-conjugated anti-rabbit
(P0448; diluted 1:2,000), anti-mouse (P0260; diluted 1:2,000) and anti-goat IgG
(P0449; diluted 1:2,000; DAKO, Glostrup, Denmark) and visualized with the ECL
system (GE Healthcare Bioscience, Piscataway, NJ, USA). Some antibody reactions
were carried out in Can Get Signal solution (TOYOBO, Tokyo, Japan) or PBS
containing 0.1% Tween 20 (Wako Pure Chemical Industries). Uncropped scans of
the blots were supplied in Supplementary Fig. 11. Analysis was carried out at least
three times and representative results are shown.
Zn2þ -Phos-tag SDS–PAGE. For phos-tag gel, whole-cell lysates were prepared
with RIPA buffer (50 mM Tris-HCl (pH 7.4), 0.15 M NaCl, 0.25% sodium
deoxycholate, 1.0% Nonidet P-40, 1.0 mM EDTA, 20 mM b-glycerophosphate,
1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 1 mM
dithiothreitol, 10 mg ml 1 aprotinin and 10 mg ml 1 leupeptin). Each sample
was mixed with a half volume of SDS–PAGE sample buffer (195 mM Tris-HCl
(pH 6.8), 3.0% SDS, 15% 2-mercaptoethanol, 30% glycerol and 0.10% bromo-
phenol blue) and heated at 95 C for 5 min. The procedures for Zn2þ -Phos-tag
SDS–PAGE were as described previously20. In brief, the acrylamide pendant
Phos-tag ligand and two equivalents of ZnCl2 were added to the separating gel
before polymerization. The running buffer consisted of 100 mM Tris and 100 mM
MOPS containing 0.10% SDS and 5.0 mM sodium bisulfite. After Zn2þ -Phos-tag
SDS–PAGE, the gel was soaked in a solution containing 25 mM Tris, 192 mM
glycine, 10% MeOH and 1.0 mM EDTA for 20 min and then soaked in a solution
containing 25 mM Tris, 192 mM glycine and 10% MeOH for 20 min. Gel transfer,
blocking, antibody reaction and detection were by the same methods as for
immunoblotting.
In vitro kinase assay. Recombinant human GST-EphA2 (70 ng) was reacted with
recombinant human active GST-RSK1 (100 ng) or RSK2 (100 ng) at 30 C for
30 min in 30 ml of reaction buffer containing 20 mM HEPES (pH 7.6), 20 mM
MgCl2, 0.2 mM ATP, 2 mM DTT, 20 mM b-glycerophosphate and 0.1 mM sodium
orthovanadate. After stopping the reaction by adding 30 ml of SDS–PAGE sample
buffer, immunoblotting was performed as described above.
Fluorescence microscopy. Cells seeded on a coverslip (Thermo Fisher Scientific,
Waltham, MA, USA) were fixed with 2% paraformaldehyde (Muto Pure
Chemicals, Tokyo, Japan) for 20 min and permeabilized with 0.5% Triton X-100
(Wako Pure Chemical Industries) for 5 min. The coverslips were overlaid with
primary antibody diluted 1:100 for EphA2 or at 5 mg ml 1 for EGFR in PBS with
0.5% BSA (Nakarai tesque, Kyoto, Japan) and incubated for 2 h, then with Alexa
Fluor 488-conjugated goat anti-rabbit IgG antibody (A11008, diluted 1:500;
Life Technologies Corporation) in PBS with 0.5% BSA for 1 h, and finally with
Rhodamine Phalloidin ‘Life Technologies Corporation’ for 30 min. After being
washed with PBS, the coverslips were inverted onto a slide with SlowFade Gold
Antifade Reagent with DAPI (Life Technologies Corporation). Fluorescence was
analysed by LSM700 confocal microscopy (Zeiss, Oberkochen, Germany). The
number of cells harbouring and losing lamellipodia in the scratched area was
counted. Image capture and quantification was performed masked to experimental
conditions. Analysis was carried out at least three times and representative results
are shown.
Scratch assay. The cells were grown as a monolayer and scratched using a pipette
tip through the monolayer. The cells were washed to remove cellular debris and
allowed to migrate for 48 h. The number of migrated cells in the scratched area was
counted. Analysis was carried out at least three times and representative results are
shown. Quantification was performed masked to experimental conditions.
Immunohistochemistry. A multi-cancer tissue microarray and a lung cancer
tissue microarray, which consist of 1,010 cores from 13 organ cancer tissues
(lung, breast, thyroid, liver, colon, stomach, prostate, ovary, uterine corpus, kidney,
pancreas, biliary tract and urothelial cancers) and 353 cores, respectively, were
obtained from Toyama University Hospital (Toyama, Japan). Detailed clinical and
pathologic information, including patient demographics, smoking history and
overall survival, was available for most patients in the lung cancer tissue micro-
array. The tumour specimens with EGFR mutations were obtained from NSCLC
patients, all of whom provided written informed consent, at Kanazawa University
Hospital (Kanazawa, Japan). This study was approved by the Institutional Review
Boards of each institute.
Immunohistochemistry was performed at Pathology Institute Corporation
(Toyama, Japan). The sections were deparaffinized and subjected to heat-induced
antigen retrieval using a water bath or a pressure chamber, blocking of the
endogenous peroxidase with 3% hydrogen peroxide for 10 min and equilibration.
Then, the sections were incubated with anti-phospho-Ser-897-EphA2 antibody
(1:100) and anti-phospho-RSK1 antibody (1:50) at room temperature overnight.
After extensive washing, the sections were incubated with EnVisionþDual Link
System-HRP (DAKO) for 30 min, visualized with DAB and counterstained with
haematoxylin, dehydrated, cleared and mounted with resinous mounting medium.
Cytoplasmic and/or cell membrane staining for phospho-Ser-897-EphA2 and
nuclear and/or cytoplasmic staining for phospho-RSK1 were considered to indicate
positivity. Image capture and evaluation was performed in a masked manner.
Statistical analysis. Statistically significant differences within each set of
categorical data were determined using two-sided Fisher’s exact tests. Overall
survival was calculated using the Kaplan–Meier method and compared by
two-sided log-rank statistics. Statistical analyses were performed using JMP
software version 11 (SAS Institute Japan, Tokyo, Japan). Probability values of
Po0.05 were considered statistically significant.
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